Ann: SPL7013 shows potent antiviral activity in RSV, page-17

i agree, this could be big.
does anyone else see the significance of the last sentence, highlighted.


"SPL7013 shows potent antiviral activity in RSV expanding use for nasal spray•New data generated demonstrates Starpharma’s antiviral nasal spray active (SPL7013) has potent antiviral activity against Respiratory Syncytial Virus (RSV)•RSV is a common and very contagious virus that affects the lungs and airways, infecting an estimated 64 million people and causing 160,000 deaths each year globally1•SPL7013 was effective against RSV when used either before or after exposure of cells to the virus, indicating that the nasal spray would be effective if used before and/or after exposure to the virus •This data, generated at a US specialist virology testing laboratory, expands the antiviral spectrum of SPL7013 from previously announced respiratory viruses,including SARS-CoV-2 (the coronavirus causing COVID-19) and influenza •Starpharma has formulated SPL7013 into a preventative nasal spray, VIRALEZETM - on track to be commercially available in H1 2021"

"Given its mechanism of action, SPL7013 has activity against a broad spectrum of viruses. In addition, in previous antiviral testing, SPL7013 has been shown to be active against multiple drug-resistant strains of viruses including HIV and HSV (h erpes simplex virus), and to not select for virus resistant to SPL7013. Therefore, SPL7013 is also expected to be active even if virus mutates, which is an advantage over traditional vaccine approaches which can be overcome by mutations (e.g. annual strain updates required for influenza vaccines). "